JAMES R TOBIN
CIK 1190128 · President & CEO · last filed 2026-05-22
JAMES R TOBIN is a President & CEO who has filed 92 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for TMDX, was dated May 22, 2026. Across all open-market trades the lifetime net is −$20.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $41.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$41.37M
9
92
-$20.75M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TMDX | Director | 162,127 | $80.21 | $13.00M | -$14.29M | 20 | 2026-05-22 |
| GMED | Director | 5,308 | $81.08 | $430.4K | -$6.43M | 18 | 2026-01-23 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | — | $0.70 | — | $0 | 4 | 2025-05-16 |
| Oxford Immunotec Global PLC (OXFD) Delisted | Director | 4,081 | — | — | $0 | 7 | 2020-06-26 |
| Corindus Vascular Robotics, Inc. (CVRS) Delisted | Director | 106,112 | — | — | $0 | 9 | 2019-10-09 |
| CHIASMA, INC (CHMA) Delisted | Director | — | $3.76 | — | $0 | 2 | 2016-06-13 |
| CRIS | Director | 72 | $4.41 | $318 | -$39.2K | 13 | 2015-01-28 |
| BSX | President & CEO | 566,550 | $49.30 | $27.93M | $0 | 4 | 2009-02-26 |
| APPLIED BIOSYSTEMS INC. (CRA) Delisted | Director | 0 | — | — | $0 | 7 | 2008-06-04 |
Recent Filings
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | TMDX | Grant (A) | +2,922 | $0 | EDGAR |
| 2026-01-23 | GMED | Grant (A) | — | $0 | EDGAR |
| 2025-05-23 | TMDX | Grant (A) | +2,134 | $0 | EDGAR |
| 2025-05-16 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-28 | GMED | Grant (A) | — | $0 | EDGAR |
| 2024-09-17 | TMDX | Gift (G) | — | $0 | EDGAR |
| 2024-08-09 | TMDX | Sell (S) | −20,000 | -$3.19M | EDGAR |
| 2024-08-08 | TMDX | Notice (144) | −20,000 | -$2.92M | EDGAR |
| 2024-06-14 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-28 | TMDX | Grant (A) | +732 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.